Tramadol Hydrochloride Extended-Release Tablets Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Tablets
Available Strengths: 100 mg, 200 mg, 300 mg
Reference Brands: Ultram(US); Tramacet, Ultracet(EU)
Category:
Analgesic
Tramadol Hydrochloride ER inhibits reuptake of serotonin and norepinephrine while activating opioid receptors, reducing pain signals centrally. Benefits include sustained pain relief for moderate to severe pain, improved mobility, and long-lasting analgesia. It offers rapid onset, fewer gastrointestinal side effects, and suitability for chronic pain management when used under supervision.
Tramadol Hydrochloride Extended-Release Tablets is available in Extended-Release Tablets
and strengths such as 100 mg, 200 mg, 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tramadol Hydrochloride Extended-Release Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tramadol Hydrochloride Extended-Release Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
OpenAI GPT-4o mini Tramadol Hydrochloride ER (Extended-Release) tablets are approved in the US and EU for moderate to severe pain management. In the US, brands like Ryzolt and ConZip are regulated by the FDA, supported by extensive clinical data, and controlled due to dependence risk. In the EU, EMA-regulated products such as Twynsta and generics require comprehensive dossiers demonstrating safety, efficacy, and manufacturing standards. Both regions enforce strict control measures, label warnings, and pharmacovigilance programs for ongoing safety monitoring. For expert assistance with dossiers, regulatory compliance, and registration, visit PharmaTradz. We support efficient market access, ensuring adherence to European and American standards for safe, effective pain therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing